Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Exenatide improves glucose control in type 2 diabetes
Última actualización 12 de septiembre de 2026
Key finding
Once-weekly exenatide significantly reduced 24-hour mean glucose level versus placebo (week 4, -1.44 vs -0.29 mmol/L).
Once-weekly exenatide significantly improved glycaemic control in adults with type 2 diabetes compared to placebo.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Once-weekly exenatide significantly improved glycaemic control in adults with type 2 diabetes compared to placebo.
Clinical relevance
These findings are significant as they suggest that once-weekly exenatide can be an effective treatment option for adults with type 2 diabetes, helping to manage blood sugar levels more effectively. Improved glycaemic control can lead to better long-term health outcomes and reduce the risk of diabetes-related complications, making it a valuable addition to diabetes management strategies.
Keep in mind
The study's sample size and demographic diversity may limit generalizability. Potential bias from self-reported outcomes could affect accuracy. Short duration of the trial may not capture long-term effects.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Juan PF, Samer N, James AR, et al. Once-Weekly Exenatide Improves Glycaemic Control and Reduces Variability in Adults with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2016;19(1):40-48. doi:10.1111/dom.12763
Efectos Principales
Once-weekly exenatide reduced 24-hour mean glucose by -1.44 mmol/L at week 4 and -1.71 mmol/L at week 10.
Fasting plasma glucose decreased by -1.65 mmol/L at week 4 and -2.32 mmol/L at week 10 with exenatide.
Participants on exenatide spent 77% of the time in euglycaemia compared to 58% in the placebo group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Exenatide and 2-hour plasma glucose, Fasting Plasma Glucose (FPG), Gastrointestinal disorders incidence, and 7 more.
This study contributes evidence to
Primary intervention
Exenatide
Primary outcomes
- 2-hour plasma glucose
- Fasting Plasma Glucose (FPG)
- Gastrointestinal disorders incidence
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
10
Evidence pairs
10
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
5
Related topics
10
Evidence pairs
1177
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 10 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Fasting Glucose
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Postprandial and OGTT Glucose
Guardar evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting Plasma Glucose (FPG)
Exenatide → Fasting Plasma Glucose (FPG)
Exenatide → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerGastrointestinal disorders incidence
Exenatide → Gastrointestinal disorders incidence
Exenatide → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerIncrease in time spent in euglycemia
Exenatide → Increase in time spent in euglycemia
Exenatide → Increase in time spent in euglycemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerMean amplitude of glycemic excursions (MAGE)
Exenatide → Mean amplitude of glycemic excursions (MAGE)
Exenatide → Mean amplitude of glycemic excursions (MAGE)
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerPostprandial blood glucose
Exenatide → Postprandial blood glucose
Exenatide → Postprandial blood glucose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerStandard deviation of glucose
Exenatide → Standard deviation of glucose
Exenatide → Standard deviation of glucose
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerTime spent in hyperglycaemic range
Exenatide → Time spent in hyperglycaemic range
Exenatide → Time spent in hyperglycaemic range
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerUrinary tract infection rate
Exenatide → Urinary tract infection rate
Exenatide → Urinary tract infection rate
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Exenatide reduced 2-hour postprandial glucose by -1.79 mmol/L at week 4.
- MAGE was reduced by -0.84 mmol/L at week 10 with exenatide.
- Time spent in hyperglycaemia decreased to 22% in the exenatide group.
A quién se aplica
- Adults aged 18-75 with type 2 diabetes.
- Participants who are inadequately controlled on current diabetes medications.
Tener en Cuenta
- Results may not apply to populations outside the study's demographic.
- Further research is needed to assess long-term safety and efficacy.
- Adverse events reported were generally mild but should be monitored.
Entre Líneas
- The study's sample size and demographic diversity may limit generalizability.
- Potential bias from self-reported outcomes could affect accuracy.
- Short duration of the trial may not capture long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Fasting Glucose, GLP-1 Receptor Agonists and Glucose Variability.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
3 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
3 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Glucose Variability Evidence Hub
All studies measuring Glucose Variability
2 studies
outcome_hubMeasures Glucose Variability as a key outcome.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Exenatide and Fasting Plasma Glucose (FPG)
Intervention: ExenatideOutcome: Fasting Plasma Glucose (FPG)
3 results
All studies on Exenatide and Mean amplitude of glycemic excursions (MAGE)
Intervention: ExenatideOutcome: Mean amplitude of glycemic excursions (MAGE)
2 results
All studies on Exenatide
Intervention: Exenatide
3 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
3 results
All studies measuring Mean amplitude of glycemic excursions (MAGE)
Outcome: Mean amplitude of glycemic excursions (MAGE)
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists improve fasting glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve fasting glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 18 supporting studies with generally consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists improve postprandial and ogtt glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve postprandial and ogtt glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
2-hour plasma glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Postprandial blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Strong Evidence
Current evidence does not show a clear effect of GLP-1 Receptor Agonists on gastrointestinal adverse events.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 12 supporting studies and existing graph evidence signals.
Do GLP-1 Receptor Agonists improve glucose variability?
Strong Evidence
GLP-1 Receptor Agonists may improve glucose variability.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Mean amplitude of glycemic excursions (MAGE)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Exenatide does not affect renal function in type 2 diabetesExenatide improves glycemic control and reduces weight in T2DM patientsBaseline features predict exenatide efficacy in type 2 diabetesNutritional Therapy and AGIs Improve Postprandial Glucose in DiabetesAerobic and resistance exercise improve blood glucose control in pre-diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.